(Q44704650)

English

Once-daily fixed-combination irbesartan 300 mg/ hydrochlorothiazide 25 mg and circadian blood pressure profile in patients with essential hypertension

scientific article published in November 2003

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

5 December 2017

Once-daily fixed-combination irbesartan 300 mg/ hydrochlorothiazide 25 mg and circadian blood pressure profile in patients with essential hypertension (English)

1 reference

Europe PubMed Central

5 December 2017

circadian rhythm

0 references

hydrochlorothiazide

1 reference

based on heuristic

inferred from title

author name string

Antonio Coca

1

1 reference

Europe PubMed Central

5 December 2017

Carlos Calvo

2

1 reference

Europe PubMed Central

5 December 2017

Javier Sobrino

3

1 reference

Europe PubMed Central

5 December 2017

Elisenda Gómez

4

1 reference

Europe PubMed Central

5 December 2017

José E López-Paz

5

1 reference

Europe PubMed Central

5 December 2017

Cristina Sierra

6

1 reference

Europe PubMed Central

5 December 2017

Ernesto Bragulat

7

1 reference

Europe PubMed Central

5 December 2017

Alejandro de la Sierra

8

1 reference

Europe PubMed Central

5 December 2017

publication date

1 November 2003

1 reference

Europe PubMed Central

5 December 2017

Clinical Therapeutics

1 reference

Europe PubMed Central

5 December 2017

25

1 reference

Europe PubMed Central

5 December 2017

11

1 reference

Europe PubMed Central

5 December 2017

2849-2864

1 reference

Europe PubMed Central

5 December 2017

The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure<SUBTITLE>The JNC 7 Report</SUBTITLE>

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980338-7

7 January 2021

based on heuristic

inferred from DOI database lookup

2003 European Society of Hypertension-European Society of Cardiology guidelines for the management of arterial hypertension

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980338-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Blood pressure, stroke, and coronary heart disease

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980338-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Randomised double-blind comparison of placebo and active treatment for older patients with isolated systolic hypertension. The Systolic Hypertension in Europe (Syst-Eur) Trial Investigators.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980338-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. UK Prospective Diabetes Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980338-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. HOT Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980338-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Effect of angiotensin-converting-enzyme inhibition compared with conventional therapy on cardiovascular morbidity and mortality in hypertension: the Captopril Prevention Project (CAPPP) randomised trial

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980338-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Randomised trial of old and new antihypertensive drugs in elderly patients: cardiovascular mortality and morbidity the Swedish Trial in Old Patients with Hypertension-2 study

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980338-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Randomised trial of effects of calcium antagonists compared with diuretics and beta-blockers on cardiovascular morbidity and mortality in hypertension: the Nordic Diltiazem (NORDIL) study

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980338-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Morbidity and mortality in patients randomised to double-blind treatment with a long-acting calcium-channel blocker or diuretic in the International Nifedipine GITS study: Intervention as a Goal in Hypertension Treatment (INSIGHT).

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980338-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Randomised trial of a perindopril-based blood-pressure-lowering regimen among 6105 individuals with previous stroke or transient ischaemic attack

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980338-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980338-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Oral administration of DuP 753, a specific angiotensin II receptor antagonist, to normal male volunteers. Inhibition of pressor response to exogenous angiotensin I and II.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980338-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Safety and tolerability of losartan potassium, an angiotensin II receptor antagonist, compared with hydrochlorothiazide, atenolol, felodipine ER, and angiotensin-converting enzyme inhibitors for the treatment of systemic hypertension

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980338-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Dose-related efficacy of irbesartan for hypertension: an integrated analysis.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980338-7

7 January 2021

based on heuristic

inferred from DOI database lookup

The effects of irbesartan added to hydrochlorothiazide for the treatment of hypertension in patients non-responsive to hydrochlorothiazide alone

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980338-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Controlled trial of losartan given concomitantly with different doses of hydrochlorothiazide in hypertensive patients.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980338-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980338-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Calculation of trough:peak ratio of antihypertensive treatment from ambulatory blood pressure: methodological aspects

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980338-7

7 January 2021

based on heuristic

inferred from DOI database lookup

The smoothness index

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980338-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Matrix study of irbesartan with hydrochlorothiazide in mild-to-moderate hypertension

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980338-7

7 January 2021

based on heuristic

inferred from DOI database lookup

The long-term antihypertensive activity and tolerability of irbesartan with hydrochlorothiazide.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980338-7

7 January 2021

based on heuristic

inferred from DOI database lookup

The antihypertensive efficacy of the combination of irbesartan and hydrochlorothiazide assessed by 24-hour ambulatory blood pressure monitoring. Irbesartan Multicenter Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980338-7

7 January 2021

based on heuristic

inferred from DOI database lookup

A randomised, double-blind comparison of the angiotensin II receptor antagonist, irbesartan, with the full dose range of enalapril for the treatment of mild-to-moderate hypertension.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980338-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Dose-related antihypertensive effects of irbesartan in patients with mild-to-moderate hypertension

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980338-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Safety of irbesartan in the treatment of mild to moderate systemic hypertension

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980338-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Alerting reaction and rise in blood pressure during measurement by physician and nurse.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980338-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Difference between office and ambulatory blood pressure and response to antihypertensive treatment

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980338-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Ambulatory blood pressure monitoring use in hypertension research and clinical practice.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980338-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Trough-to-peak ratio, smoothness index, and circadian blood pressure profile after treatment with once-daily fixed combination of losartan 100 and hydrochlorothiazide 25 in essential hypertension

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980338-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Trough:peak ratio and smoothness index in the evaluation of 24-h blood pressure control in hypertension: a comparative study between valsartan/hydrochlorothiazide combination and amlodipine

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980338-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Twenty-four hour ambulatory blood pressure in the International Nifedipine GITS Study Intervention as a Goal in Hypertension Treatment (INSIGHT).

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980338-7

7 January 2021

based on heuristic

inferred from DOI database lookup

The smoothness index, but not the trough-to-peak ratio predicts changes in carotid artery wall thickness during antihypertensive treatment

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980338-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Hypokalemia associated with diuretic use and cardiovascular events in the Systolic Hypertension in the Elderly Program

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980338-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1016/S0149-2918(03)80338-7

1 reference

Europe PubMed Central

5 December 2017

1 reference

Europe PubMed Central

5 December 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q44704650&oldid=2098840362"